Brain-specific cytoskeletal damage markers in cerebrospinal fluid: Is there a common pattern between amyotrophic lateral sclerosis and primary progressive multiple sclerosis?

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 17565-17588

  Abdelhak, Ahmed ^a   Junker, Andreas ^b   Brettschneider, Johannes ^a   Kassubek, Jan ^a   Ludolph, Albert C ^a   Otto, Markus ^a   Tumani, Hayrettin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Amyotrophic lateral sclerosis (ALS); Biomarker; Neurofilaments; Primary progressive multiple sclerosis (PPMS); Tau; Tubulin

Indexed keywords

ACTIN; BETA TUBULIN; BIOLOGICAL MARKER; CXCL13 CHEMOKINE; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 1; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; TUBULIN;

AMYOTROPHIC LATERAL SCLEROSIS; AXONAL INJURY; CEREBROSPINAL FLUID ANALYSIS; CHEMOLUMINESCENCE; CYTOSKELETON; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOKED MUSCLE RESPONSE; GENE MUTATION; HUMAN; INFLAMMATORY INFILTRATE; MINI MENTAL STATE EXAMINATION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; VOLUMETRY; BRAIN; BRAIN INJURY; CEREBROSPINAL FLUID; GENETICS; METABOLISM; MOTONEURON; PATHOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; BRAIN; BRAIN INJURIES; CYTOSKELETON; HUMANS; MOTOR NEURONS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TAU PROTEINS; TUBULIN;

EID: 84938531731     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160817565     Document Type: Review

References (111)

1. Luessi, F.; Siffrin, V.; Zipp, F. Neurodegeneration in multiple sclerosis: Novel treatment strategies. Expert Rev. Neurother. 2012, 12, 1061-1076.
2. Koch, M.; Kingwell, E.; Rieckmann, P.; Tremlett, H.; Neurologists, U. M. C. The natural history of secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2010, 81, 1039-1043.
3. Thompson, A. J.; Polman, C. H.; Miller, D. H.; McDonald, W. I.; Brochet, B.; Filippi, M. M. X.; de Sa, J. Primary progressive multiple sclerosis. Brain 1997, 120, 1085-1096.
4. Frischer, J. M.; Bramow, S.; Dal-Bianco, A.; Lucchinetti, C. F.; Rauschka, H.; Schmidbauer, M.; Laursen, H.; Sorensen, P. S.; Lassmann, H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132, 1175-1189.
5. Feinstein, A.; Freeman, J.; Lo, A. C. Treatment of progressive multiple sclerosis: What works, what does not, and what is needed. Lancet neurol. 2015, 14, 194-207.
6. Ferguson, T. A.; Elman, L. B. Clinical presentation and diagnosis of amyotrophic lateral sclerosis. NeuroRehabilitation 2007, 22, 409-416.
7. Vucic, S.; Rothstein, J. D.; Kiernan, M. C. Advances in treating amyotrophic lateral sclerosis: Insights from pathophysiological studies. Trends Neurosci. 2014, 37, 443-442.
8. Traxinger, K.; Kelly, C.; Johnson, B. A.; Lyles, R. H.; Glass, J. D. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011. Neurol. Clin. Pract. 2013, 3, 313-320.
9. Neumann, M.; Sampathu, D. M.; Kwong, L. K.; Truax, A. C.; Micsenyi, M. C.; Chou, T. T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C. M.; et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314, 130-133.
10. Van Den Bosch, L.; van Damme, P.; Bogaert, E.; Robberecht, W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762, 1068-1082.
11. Rice, C. M.; Cottrell, D.; Wilkins, A.; Scolding, N. J. Primary progressive multiple sclerosis: Progress and challenges. J. Neurol. Neurosurg. Psychiatry 2013, 84, 1100-1106.
12. Martola, J.; Stawiarz, L.; Fredrikson, S.; Hillert, J.; Bergstrom, J.; Flodmark, O.; Kristoffersen Wiberg, M. Progression of non-age-related callosal brain atrophy in multiple sclerosis: A 9-year longitudinal MRI study representing four decades of disease development. J. Neurol. Neurosurg. Psychiatry 2007, 78, 375-380.
13. El Mendili, M. M.; Cohen-Adad, J.; Pelegrini-Issac, M.; Rossignol, S.; Morizot-Koutlidis, R.; Marchand-Pauvert, V.; Iglesias, C.; Sangari, S.; Katz, R.; Lehericy, S.; et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS ONE 2014, 9, e95516.
14. Faber, I.; Servelhere, K. R.; Martinez, A. R.; D'Abreu, A.; Lopes-Cendes, I.; Franca-Jr, M. C. Clinical features and management of hereditary spastic paraplegia. Arq. Neuropsiquiatr. 2014, 72, 219-226.
15. Gordon, P. H.; Cheng, B.; Katz, I. B.; Pinto, M.; Hays, A. P.; Mitsumoto, H.; Rowland, L. P. The natural history of primary lateral sclerosis. Neurology 2006, 66, 647-653.
16. Miller, D. H.; Leary, S. M. Primary-progressive multiple sclerosis. Lancet Neurol. 2007, 6, 903-912.
17. Gotkine, M.; Argov, Z. Clinical differentiation between primary lateral sclerosis and upper motor neuron predominant amyotrophic lateral sclerosis-Author reply. Arch. Neurol. 2007, 64, 1545.
18. Gordon, P. H. Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013, 4, 295-310.
19. Blokhuis, A. M.; Groen, E. J.; Koppers, M.; van den Berg, L. H.; Pasterkamp, R. J. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013, 125, 777-794.
20. Freischmidt, A.; Wieland, T.; Richter, B.; Ruf, W.; Schaeffer, V.; Muller, K.; Marroquin, N.; Nordin, F.; Hubers, A.; Weydt, P.; et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015, 18, 631-636.
21. Lee, E. B.; Lee, V. M.; Trojanowski, J. Q. Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 2012, 13, 38-50.
22. Dormann, D.; Rodde, R.; Edbauer, D.; Bentmann, E.; Fischer, I.; Hruscha, A.; Than, M. E.; Mackenzie, I. R.; Capell, A.; Schmid, B.; et al. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 2010, 29, 2841-2857.
23. Ogawa, M.; Furukawa, Y. A seeded propagation of Cu, Zn-superoxide dismutase aggregates in amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2014, 8, doi: 10. 3389/fncel. 2014. 00083.
24. Lagier-Tourenne, C.; Polymenidou, M.; Cleveland, D. W. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010, 19, R46-R64.
25. Rutherford, N. J.; Zhang, Y. J.; Baker, M.; Gass, J. M.; Finch, N. A.; Xu, Y. F.; Stewart, H.; Kelley, B. J.; Kuntz, K.; Crook, R. J.; et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008, 4, e1000193.
26. Li, Y. R.; King, O. D.; Shorter, J.; Gitler, A. D. Stress granules as crucibles of als pathogenesis. J. Cell Biol. 2013, 201, 361-372.
27. Zinszner, H.; Sok, J.; Immanuel, D.; Yin, Y.; Ron, D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 1997, 110, 1741-1750.
28. Dormann, D.; Haass, C. TDP-43 and FUS: A nuclear affair. Trends Neurosci. 2011, 34, 339-348.
29. McGeer P. L.; McGeer E. G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26, 459-470.
30. Valori, C. F.; Brambilla, L.; Martorana, F.; Rossi, D. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2014, 71, 287-297.
31. Zhao, W.; Beers, D. R.; Appel, S. H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013, 8, 888-899.
32. Brites, D.; Vaz, A. R. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front. Cell. Neurosci. 2014, 8, doi: 10. 3389/fncel. 2014. 00117.
33. Lee, Y.; Morrison, B. M.; Li, Y.; Lengacher, S.; Farah, M. H.; Hoffman, P. N.; Liu, Y.; Tsingalia, A.; Jin, L.; Zhang, P. W.; et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487, 443-448.
34. Mantovani, S.; Garbelli, S.; Pasini, A.; Alimonti, D.; Perotti, C.; Melazzini, M.; Bendotti, C.; Mora, G. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 2009, 210, 73-79.
35. Neymotin, A.; Petri, S.; Calingasan, N. Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M. F.; Kiaei, M. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 220, 191-197.
36. Kang, J.; Rivest, S. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J. Cell Biol. 2007, 179, 1219-1230.
37. Brettschneider, J.; del Tredici, K.; Toledo, J. B.; Robinson, J. L.; Irwin, D. J.; Grossman, M.; Suh, E.; van Deerlin, V. M.; Wood, E. M.; Baek, Y.; et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 2013, 74, 20-38.
38. Ravits, J. M.; La Spada, A. R. ALS motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009, 73, 805-811.
39. Ravits, J.; Appel, S.; Baloh, R. H.; Barohn, R.; Brooks, B. R.; Elman, L.; Floeter, M. K.; Henderson, C.; Lomen-Hoerth, C.; Macklis, J. D.; et al. Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph. Lateral Scler. Front. Degener. 2013, 14 (Suppl. 1), 5-18.
40. Bruck, W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol. 2005, 252 (Suppl. 5), v3-v9.
41. Munzel, E. J.; Williams, A. Promoting remyelination in multiple sclerosis-Recent advances. Drugs 2013, 73, 2017-2029.
42. Patani, R.; Balaratnam, M.; Vora, A.; Reynolds, R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol. Appl. Neurobiol. 2007, 33, 277-287.
43. Patrikios, P.; Stadelmann, C.; Kutzelnigg, A.; Rauschka, H.; Schmidbauer, M.; Laursen, H.; Sorensen, P. S.; Bruck, W.; Lucchinetti, C.; Lassmann, H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129, 3165-3172.
44. Lassmann, H.; van Horssen, J.; Mahad, D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat. Rev. Neurol. 2012, 8, 647-656.
45. Lucchinetti, C. F.; Bruck, W.; Rodriguez, M.; Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996, 6, 259-274.
46. Lucchinetti, C.; Bruck, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; Lassmann, H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47, 707-717.
47. Hauser, S. L.; Oksenberg, J. R. The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron 2006, 52, 61-76.
48. Lassmann, H. Multiple sclerosis: Is there neurodegeneration independent from inflammation? J. Neurol. Sci. 2007, 259, 3-6.
49. Fu, L.; Matthews, P. M.; de Stefano, N.; Worsley, K. J.; Narayanan, S.; Francis, G. S.; Antel, J. P.; Wolfson, C.; Arnold, D. L. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998, 121, 103-113.
50. Tumani, H.; Hartung, H. P.; Hemmer, B.; Teunissen, C.; Deisenhammer, F.; Giovannoni, G.; Zettl, U. K.; BioMS Study Group. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35, 117-127.
51. Lassmann, H. Mechanisms of white matter damage in multiple sclerosis. Glia 2014, 62, 1816-1830.
52. Davson, H.; Hollingsworth, G.; Segal, M. B. The mechanism of drainage of the cerebrospinal fluid. Brain 1970, 93, 665-678.
53. Felgenhauer, K.; Schliep, G.; Rapic, N. Evaluation of the blood-CSF barrier by protein gradients and the humoral immune response within the central nervous system. J. Neurol. Sci. 1976, 30, 113-128.
54. Reiber, H. Flow rate of cerebrospinal fluid (CSF)-A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994, 122, 189-203.
55. Felgenhauer, K. The filtration concept of the blood-CSF-barrier as basis for the differentiation of CSF proteins. In New Concepts of A Blood-Brain Barrier; Springer US: New York, NY, USA, 1995; pp. 209-217.
56. Reiber, H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 2001, 310, 173-186.
57. Semra, Y. K.; Seidi, O. A.; Sharief, M. K. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol. 2002, 122, 132-139.
58. Teunissen, C. E.; Khalil, M. Neurofilaments as biomarkers in multiple sclerosis. Mult. Scler. 2012, 18, 552-556.
59. Kuhle, J.; Plattner, K.; Bestwick, J. P.; Lindberg, R. L.; Ramagopalan, S. V.; Norgren, N.; Nissim, A.; Malaspina, A.; Leppert, D.; Giovannoni, G.; et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult. Scler. 2013, 19, 1597-1603.
60. Yabe, J. T.; Chylinski, T.; Wang, F. S.; Pimenta, A.; Kattar, S. D.; Linsley, M. D.; Chan, W. K. H.; Shea, T. B. Neurofilaments consist of distinct populations that can be distinguished by C-terminal phosphorylation, bundling, and axonal transport rate in growing axonal neurites. J. Neurosci. 2001, 21, 2195-2205.
61. Strong, M. J. Neurofilament metabolism in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 1999, 169, 170-177.
62. Fuchs, E.; Cleveland, D. W. A structural scaffolding of intermediate filaments in health and disease. Science 1998, 279, 514-519.
63. Dujmovic, I. Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. Mult. Scler. Int. 2011, 2011, doi: 10. 1155/2011/767083.
64. Gresle, M. M.; Shaw, G.; Jarrott, B.; Alexandrou, E. N.; Friedhuber, A.; Kilpatrick, T. J.; Butzkueven, H. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2008, 86, 3548-3555.
65. Liu, Q.; Xie, F.; Siedlak, S. L.; Nunomura, A.; Honda, K.; Moreira, P. I.; Zhua, X.; Smith, M. A.; Perry, G. Neurofilament proteins in neurodegenerative diseases. Cell. Mol. Life Sci. 2004, 61, 3057-3075.
66. Munoz, D. G.; Greene, C.; Perl, D. P.; Selkoe, D. J. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol. 1988, 47, 9-18.
67. Figlewicz, D. A.; Krizus, A.; Martinoli, M. G.; Meininger, V.; Dib, M.; Rouleau, G. A.; Julien, J. P. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 1994, 3, 1757-1761.
68. Rosengren, L. E.; Karlsson, J. E.; Karlsson, J. O.; Persson, L. I.; Wikkelso, C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996, 67, 2013-2018.
69. Brettschneider, J.; Petzold, A.; Sussmuth, S. D.; Ludolph, A. C.; Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006, 66, 852-856.
70. Reijn, T. S.; Abdo, W. F.; Schelhaas, H. J.; Verbeek, M. M. CSF neurofilament protein analysis in the differential diagnosis of ALS. J. Neurol. 2009, 256, 615-619.
71. Zetterberg, H.; Jacobsson, J.; Rosengren, L.; Blennow, K.; Andersen, P. M. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1 genotype. Eur. J. Neurol. 2007, 14, 1329-1333.
72. Tortelli, R.; Ruggieri, M.; Cortese, R.; D'Errico, E.; Capozzo, R.; Leo, A.; Mastrapasqua, M.; Zoccolella, S.; Leante, R.; Livrea, P.; et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: A possible marker of disease severity and progression. Eur. J. Neurol 2012, 19, 1561-1567.
73. Boylan, K. B.; Glass, J. D.; Crook, J. E.; Yang, C.; Thomas, C. S.; Desaro, P.; Johnston, A.; Overstreet, K.; Kelly, C.; Polak, M.; et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and csf as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2013, 84, 467-472.
74. Lu, C. H.; Macdonald-Wallis, C.; Gray, E.; Pearce, N.; Petzold, A.; Norgren, N.; Giovannoni, G.; Fratta, P.; Sidle, K.; Fish, M.; et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015, 84, 2247-2257.
75. Kuhle, J.; Regeniter, A.; Leppert, D.; Mehling, M.; Kappos, L.; Lindberg, R. L.; Petzold, A. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J. Neuroimmunol. 2010, 220, 114-119.
76. Petzold, A.; Eikelenboom, M. J.; Keir, G.; Grant, D.; Lazeron, R. H.; Polman, C. H.; Uitdehaag, B. M.; Thompson, E. J.; Giovannoni, G. Axonal damage accumulates in the progressive phase of multiple sclerosis: Three year follow up study. J. Neurol. Neurosurg. Psychiatry 2005, 76, 206-211.
77. Romme Christensen, J.; Bornsen, L.; Khademi, M.; Olsson, T.; Jensen, P. E.; Sorensen, P. S.; Sellebjerg, F. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult. Scler. 2013, 19, 877-884.
78. Eikelenboom, M. J.; Petzold, A.; Lazeron, R. H.; Silber, E.; Sharief, M.; Thompson, E. J.; Barkhof, F.; Giovannoni, G.; Polman, C. H.; Uitdehaag, B. M. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003, 60, 219-223.
79. Salzer, J.; Svenningsson, A.; Sundstrom, P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 2010, 16, 287-292.
80. Madeddu, R.; Farace, C.; Tolu, P.; Solinas, G.; Asara, Y.; Sotgiu, M. A.; Delogu, L. G.; Prados, J. C.; Sotgiu, S.; Montella, A. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol. Sci. 2013, 34, 181-186.
81. Shahani, N.; Brandt, R. Functions and malfunctions of the tau proteins. Cell. Mol. Life Sci. 2002, 59, 1668-1680.
82. Jimenez-Jimenez, F. J.; Hernanz, A.; Medina-Acebron, S.; de Bustos, F.; Zurdo, J. M.; Alonso, H.; Puertas, I.; Barcenilla, B.; Sayed, Y.; Cabrera-Valdivia, F. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2005, 111, 114-117.
83. Paladino, P.; Valentino, F.; Piccoli, T.; Piccoli, F.; La Bella, V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009, 16, 257-261.
84. Grossman, M.; Elman, L.; McCluskey, L.; McMillan, C. T.; Boller, A.; Powers, J.; Rascovsky, K.; Hu, W.; Shaw, L.; Irwin, D. J., et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014, doi: 10. 1001/jamaneurol. 2013. 6064.
85. Sussmuth, S. D.; Tumani, H.; Ecker, D.; Ludolph, A. C. Amyotrophic lateral sclerosis: Disease stage related changes of tau protein and S100 β in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett. 2003, 353, 57-60.
86. Kapaki, E.; Paraskevas, G. P.; Michalopoulou, M.; Kilidireas, K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur. Neurol. 2000, 43, 228-232.
87. Brettschneider, J.; Maier, M.; Arda, S.; Claus, A.; Sussmuth, S. D.; Kassubek, J.; Tumani, H. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult. Scler. 2005, 11, 261-265.
88. Terzi, M.; Birinci, A.; Cetinkaya, E.; Onar, M. K. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol. Scand. 2007, 115, 325-330.
89. Bartosik-Psujek, H.; Archelos, J. J. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J. Neurol. 2004, 251, 414-420.
90. Guimaraes, I.; Cardoso, M. I.; Sa, M. J. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult. Scler. 2006, 12, 354-356.
91. Colucci, M.; Roccatagliata, L.; Capello, E.; Narciso, E.; Latronico, N.; Tabaton, M.; Mancardi, G. L. The 14-3-3 protein in multiple sclerosis: A marker of disease severity. Mult. Scler. 2004, 10, 477-481.
92. Anderson, J. M.; Patani, R.; Reynolds, R.; Nicholas, R.; Compston, A.; Spillantini, M. G.; Chandran, S. Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathol. 2010, 119, 591-600.
93. Downing, K. H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell Dev. Biol. 2000, 16, 89-111.
94. Laferriere, N. B.; MacRae, T. H.; Brown, D. L. Tubulin synthesis and assembly in differentiating neurons. Biochem. Cell Biol. 1997, 75, 103-117.
95. Gunning, P.; Hardeman, E.; Jeffrey, P.; Weinberger, R. Creating intracellular structural domains: Spatial segregation of actin and tropomyosin isoforms in neurons. Bioessays 1998, 20, 892-900.
96. Doussau, F.; Augustine, G. J. The actin cytoskeleton and neurotransmitter release: An overview. Biochimie 2000, 82, 353-363.
97. Tumani, H.; Teunissen, C.; Süssmuth, S.; Otto, M.; Ludolph, A. C.; Brettschneider, J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev. Mol. Diagn. 2008, 8, 479-494.
98. Vinsant, S.; Mansfield, C.; Jimenez-Moreno, R.; del Gaizo Moore, V.; Yoshikawa, M.; Hampton, T. G.; Prevette, D.; Caress, J.; Oppenheim, R. W.; Milligan, C. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: Part II, results and discussion. Brain Behav. 2013, 3, 431-457.
99. Vinsant, S.; Mansfield, C.; Jimenez-Moreno, R.; del Gaizo Moore, V.; Yoshikawa, M.; Hampton, T. G.; Prevette, D.; Caress, J.; Oppenheim, R. W.; Milligan, C. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: Part I, background and methods. Brain Behav. 2013, 3, 335-350.
100. De Carvalho, M.; Swash, M. The onset of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2006, 77, 388-389.
101. Aggarwal, A.; Nicholson, G. Normal complement of motor units in asymptomatic familial (SOD1 mutation) amyotrophic lateral sclerosis carriers. J. Neurol. Neurosurg. Psychiatry 2001, 71, 478-481.
102. Magnus, T.; Beck, M.; Giess, R.; Puls, I.; Naumann, M.; Toyka, K. V. Disease progression in amyotrophic lateral sclerosis: Predictors of survival. Muscle Nerve 2002, 25, 709-714.
103. Agosta, F.; Valsasina, P.; Riva, N.; Copetti, M.; Messina, M. J.; Prelle, A.; Comi, G.; Filippi, M. The cortical signature of amyotrophic lateral sclerosis. PLoS ONE 2012, 7, e42816.
104. Verstraete, E.; van den Heuvel, M. P.; Veldink, J. H.; Blanken, N.; Mandl, R. C.; Hulshoff Pol, H. E.; van den Berg, L. H. Motor network degeneration in amyotrophic lateral sclerosis: A structural and functional connectivity study. PLoS ONE 2010, 5, e13664.
105. Mezzapesa, D. M.; D'Errico, E.; Tortelli, R.; Distaso, E.; Cortese, R.; Tursi, M.; Federico, F.; Zoccolella, S.; Logroscino, G.; Dicuonzo, F.; et al. Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS ONE 2013, 8, e80748.
106. Menke, R. A.; Korner, S.; Filippini, N.; Douaud, G.; Knight, S.; Talbot, K.; Turner, M. R. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014, 137, 2546-2555.
107. Kwan, J. Y.; Meoded, A.; Danielian, L. E.; Wu, T.; Floeter, M. K. Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin. 2012, 2, 151-160.
108. Fisher, E.; Lee, J. C.; Nakamura, K.; Rudick, R. A. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann. Neurol. 2008, 64, 255-265.
109. Lukas, C.; Knol, D. L.; Sombekke, M. H.; Bellenberg, B.; Hahn, H. K.; Popescu, V.; Weier, K.; Radue, E. W.; Gass, A.; Kappos, L.; et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2014, doi: 10. 1136/jnnp-2014-308021.
110. Agosta, F.; Absinta, M.; Sormani, M. P.; Ghezzi, A.; Bertolotto, A.; Montanari, E.; Comi, G.; Filippi, M. In vivo assessment of cervical cord damage in MS patients: A longitudinal diffusion tensor MRI study. Brain 2007, 130, 2211-2219.
111. Okuda, D. T.; Siva, A.; Kantarci, O.; Inglese, M.; Katz, I.; Tutuncu, M.; Keegan, B. M.; Donlon, S.; le Hua, H.; Vidal-Jordana, A.; et al. Radiologically isolated syndrome: 5-Year risk for an initial clinical event. PLoS ONE 2014, 9, e90509.